Amsterdam University Medical Centers, location VUmc
Amsterdam, Netherlands
Location status: Recruiting
NCT Number: NCT06068582
The goal of this randomized controlled trial is to compare the effectiveness of two innovative interventions aimed at preventing cognitive decline and work-related problems to enhanced usual care in improving quality of life in people with multiple sclerosis. Secondary objectives are:
* to compare the effectiveness of the investigated interventions in improving cognitive, psychological, and work functioning, and in enhancing the brain's functional network * to examine which factors (i.e., baseline cognitive, psychological, work, and brain MRI-parameters) are predictive of the response to the investigated interventions * aim to qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice
Participants will follow the intervention for four months, with follow-up measurements at six months after intervention and 12 months after intervention.
Interested in participating?
Request Info18 year–67 year
All sexes
Interventional
Not applicable
Amsterdam, Netherlands
Location status: Recruiting
Background Up to 65% of the people with multiple sclerosis (PwMS) develop cognitive deficits that severely affect daily life functioning and PwMS' quality of life. Moreover, approximately 65% of all patients end up unemployed within five years after diagnosis. Current treatments mostly focus on symptom management and return to work, which may be too late. It is hypothesized that timely interventions will help prevent or delay cognitive decline and work-related problems in PwMS, thereby improving quality of life.
Objectives
Primary Objective:
To compare the effectiveness of the investigated interventions with enhanced usual care in improving quality of life.
Secondary Objectives:
Material and methods A randomized controlled trial with three arms and three follow-up visits over a total time period of 16 months. During these visits researchers will gather information from questionnaires, neuropsychological examination, MRI and blood sampling. All participants (N= 240) have a confirmed MS diagnosis according to the McDonald 2017 criteria, have subclinical cognitive impairment and are aged between 18 and 67. Participants will be randomly assigned to one of the three arms (N=90 in each arm). Interviews will be conducted with 12-15 participants from both interventions, 10-12 sport coaches, 8-12 work coaches and 10-12 supervisors from the workplace.
'Strengthening the brain' (4 month-program) consists of weekly 30 minutes 1-on-1 exercise and lifestyle coaching in combination with two moments per week unsupervised exercises at home and a home-based online computerized cognitive training. 'Strengthening the mind' (4 month-program) consists of biweekly contact with work coaches who are all diagnosed with MS themselves. 'Enhanced usual care' entails an appointment with a researcher in addition to usual care.
Results The primary outcome is change in quality of life as measured with the 36-item Short Form. Several secondary outcomes will be collected: cognitive, psychological, cost-effectiveness, structural- and functional brain, neurological, physiological, and qualitative measures.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
Time frame: Baseline, Month 4, Month 10, and Month 16
Quality of life assessed using the 36-item Short Form. Item-scores are summed and transformed into a total score that ranges 0-100. Higher score corresponds with better quality of life.
Time frame: Baseline, Month 4, Month 10, and Month 16
Information processing speed is assessed using the Symbol Digit Modalities Test (SMDT). The total responses made in 90 seconds is administered. Higher amount of correct responses equals better information processing speed.
Time frame: Baseline, Month 4, Month 10, and Month 16
Information processing speed is assessed using the Paced Auditory Serial Addition Test (PASAT). The total correct answers given, out of 60, is administered. Higher amount of correct responses equals better information processing speed.
Time frame: Baseline, Month 4, Month 10, and Month 16
Verbal fluency is assessed using the Dutch adaptation of the Controlled Oral Word Association Test; Dutch Letter Fluency Test. Total number of correct words will be administered. Higher score corresponds with better verbal fluency.
Time frame: Baseline, Month 4, Month 10, and Month 16
Spatial Processing is assessed using the Judgement of Line Orientation. Total correct responses, with maximum 30, will be administered. Higher score corresponds with better spatial processing.
Time frame: Baseline, Month 4, Month 10, and Month 16
New Learning and Memory is assessed using the California Verbal Learning Test, second edition (CVLT-II). Direct recall on the CVLT-II will be administered using number of correctly remembered items over learning trials 1-5. Delayed recall on CVLT-II will be administered using number of correctly remembered items 20 minutes after learning trail 5. Maximum scores for direct recall, delayed recall, and recognition are set at 80, 16, and 44, respectively. Higher score equals better verbal learning and memory.
Time frame: Baseline, Month 4, Month 10, and Month 16
New Learning and Memory is assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). Direct recall on BVMT-R will be administered using number of correctly remembered items over learning trials 1-3. Delayed recall on BVMT-R will be administered using number of correctly remembered items 25 minutes after learning trail 3. Maximum scores for direct recall, delayed recall, and recognition are set at 36, 12, and 12, respectively. Higher score equals better visual learning and memory.
Time frame: Baseline, Month 4, Month 10, and Month 16
Executive Function is assessed using the Delis-Kaplan Executive Function System. Total correct sorts will be administered, with a maximum of 16 sorts. A higher score suggests better executive functioning.
Time frame: Baseline, Month 4, Month 10, and Month 16
Self-Reported Cognitive Functioning is assessed using the Multiple Sclerosis Neuropsychological Screening Questionnaire. Maximum score of 70 can be reached, with a score of 27 or higher indicating presence of neuropsychological problems.
Time frame: Baseline, Month 4, Month 10, and Month 16
Work Participation and Productivity is assessed using the Work Productivity and Activity Impairment Questionnaire: General Health, which administers the effect of health-problems on ability to work. Scores are calculated as percentages, with higher numbers indicating greater impairment and less productivity.
Time frame: Baseline, Month 4, Month 10, and Month 16
Work Difficulties are assessed using the Multiple Sclerosis Work Difficulties Questionnaire. The questionnaire consists of 23 items, which can be grouped into three subscales: psychological/cognitive barriers, physical barriers, and external barriers. The maximum score of each subscale is 100, with higher scores indicating higher perceived difficulties. Total score consists of an average of the three subscale scores.
Time frame: Baseline, Month 4, Month 10, and Month 16
Capability to carry out Work Activities is assessed using the Capability Set for Work Questionnaire. This questionnaire evaluates for seven valued work aspects whether, A) it is important to the worker, B) their work offers sufficient opportunities to do it, and C) it can be achieved, on a 5-point Likert scale.
Time frame: Baseline, Month 4, Month 10, and Month 16
Quality of Working Life is assessed using the Quality of Working Life Questionnaire for Cancer Survivors. The questionnaire consists of five subscales: meaning of work, perception of the work situation, atmosphere in the work environment, understandings and recognition in the organisation, and problems due to health situation. The overall score and sum scores of the subscales are calculated with a standardised score 0-100. Higher score corresponds with better quality of working life.
Time frame: Baseline, Month 4, and Month 16
Grey Matter Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
Time frame: Baseline, Month 4, and Month 16
White Matter Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
Time frame: Baseline, Month 4, and Month 16
Total Brain Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
Time frame: Baseline, Month 4, and Month 16
Volumes of Deep Grey Matter Structures will be determined using FIRST.
Time frame: Baseline, Month 4, and Month 16
Cortical Thickness will be determined using Freesurfer.
Time frame: Baseline, Month 4, and Month 16
White Matter Integrity will be determined using Diffusion Tensor Imaging
Time frame: Baseline, Month 4, and Month 16
Functional Connectivity will be determined using Resting-State fMRI
Time frame: Baseline, Month 4, and Month 16
Regional Functional Activation will be determined using Task-Based fMRI
Time frame: Baseline, Month 4, Month 10, and Month 16
Fatigue will be assessed using the Checklist Individual Strength. The questionnaire consists of 20 items, scored on a 7-point Likert scale. Fatigue is a subscale of the questionnaire, and is scored by adding the scores of the items, where a higher score corresponds with more fatigue.
Time frame: Baseline, Month 4, Month 10, and Month 16
Mood and Anxiety will be assessed using the Hospital Anxiety and Depression Scale. The questionnaire consists of 14 items on a 4-point Likert scale. The range of scores is 0-21 where a higher score equals more complaints of anxiety and depression.
Time frame: Baseline, Month 4, Month 10, and Month 16
Resilience will be assessed using the Connor Davidson Resilience Scale. Total score ranges 0-100, with higher scores reflecting greater resilience.
Time frame: Baseline, Month 4, Month 10, and Month 16
Perceived Level of Stress will be assessed using the Perceived Stress Scale. Total score ranges 0-40, with higher scores indicating higher perceived stress.
Time frame: Baseline, Month 4, Month 10, and Month 16
Social Mindfulness will be assessed using the SoMi paradigm by van Doesum et al. (2013). Choices that are made are scores as mindful (1) or unmindful (0). Final score will be computed by averaging the scores over all decisions, resulting in a number between 0 (unmindful) and 1 (mindful).
Time frame: Baseline, Month 4, Month 10, and Month 16
Social Participation will be assessed using the PROMIS 'Ability to Participate in Social Roles and Activities' item bank. The questionnaire consists of eight items that can be scored on a 5-point Likert scale. Higher scores indicate better ability to participate in social roles and activities.
Time frame: Baseline, Month 4, Month 10, and Month 16
MS-related disability will be assessed using the Expanded Disability Status Scale. This scale ranges from 0.0 to 10.0, where a higher score indicates worse disability.
Time frame: Baseline, Month 4, and Month 16
Balance will be assessed using the Mini-BESTest. The test contains 14 items where a total score of 28 points can be achieved, where a score <19 induces an increased risk of falling.
Time frame: Baseline, Month 4, and Month 16
Walking Speed will be assessed using the Timed 25-Foot Walk.
Time frame: Baseline, Month 4, and Month 16
Endurance will be assessed using the Shuttle Walk Test according to the protocol of Singh et al. (1992).
Time frame: Baseline, Month 4, and Month 16
Grip Strength will be assessed using a JAMAR hand-held dynamometer.
Time frame: Baseline, Month 4, and Month 16
Upper Limb Dexterity will be assessed using the 9-Hole Peg Test and the Purdue Pegboard Test.
Time frame: Baseline, Month 4, Month 10, and Month 16
Lost Productivity Costs will be assessed using the iMTA Productivity Cost Questionnaire. The questionnaire consists of three modules measuring absenteeism, presenteeism, and productivity loss from unpaid work.
Time frame: Baseline, Month 4, Month 10, and Month 16
Societal Costs will be assessed using the iMTA Medical Consumption Questionnaire.
Time frame: Baseline, Month 4, Month 10, and Month 16
Quality Adjusted Life Years will be assessed using the EuroQol five-dimensional Questionnaire. The questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Higher scores indicate more problems considering the dimensions.
Contact information is provided by the study sponsor or research team.
Jip Aarts
CONTACT
Shalina Saddal
CONTACT
Amsterdam UMC, location VUmc
Other
Acronym: DBL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738120
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Pontevedra, Spain
View Trial DetailsNCT06410261
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Chicago, Illinois, United States
View Trial DetailsNCT05051618
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Chicago, Illinois, United States
View Trial DetailsNCT07536503
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Ankara, Turkey (Türkiye)
View Trial Details